论文部分内容阅读
中国医学科学院皮肤病研究所、南京药学院与江苏泰州制药厂等单位协作研制成功的治疗免疫性疾病新药雷公藤总甙(T-_Ⅱ,以下简称总甙)是从雷公藤中提取、精制而得的有较强抗炎及免疫抑制作用的有效组分。该药经实验动物的琼脂关节肿试验、毛细血管通透性试验、棉球肉芽肿试验等证明,总甙具有显著的抗炎作用;经溶血素测定或溶血空斑试验、脾细胞免疫特异花环试验等证明总甙对体液免疫有抑制作用。此外,经人的体外试验和动物的体内、体外试验,如淋巴细胞转化及E 花环形成试验及豚鼠OT 皮肤试验和小鼠胸腺重量测定等证明总甙对细胞免疫有抑制作用。
Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing Pharmaceutical College and Jiangsu Taizhou Pharmaceutical Factory and other units to successfully co-developed the treatment of immune diseases new drug Tripterygium total glycosides (T-_ Ⅱ, hereinafter referred to as glycosides) is extracted from Tripterygium, refined and Have a strong anti-inflammatory and immunosuppressive effects of effective components. The drug by agar joint swollen test animals, capillary permeability test, cotton ball granuloma test proved that glycosides have a significant anti-inflammatory effect; hemolysin or hemolytic plaque test, spleen cell-specific immune wreath Test proved that glycosides inhibit humoral immunity. In addition, in vitro experiments and animal in vivo and in vitro tests, such as lymphocyte transformation and E rosette formation test and guinea pig OT skin test and mouse thymus weight determination proved that glycosides inhibit cellular immunity.